Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Trump’s Arlington Arch Project Faces New Court Restrictions 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Japanese Yen Nears Seven-Month High as Oil Approaches $100 
UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
White House Weighs Refined Copper Tariffs as Cost Concerns Grow 
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates 
Brent Oil Tops $100 as Middle East Conflict Threatens Supply 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
US Judge Dismisses Gautam Adani Criminal Charges 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Gold Prices Rebound as Dollar Weakens, Fed Decision Looms 
Add as a preferred source on Google
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
